Dyadic International to Present at PEGS 2017, The Essential Protein Engineering Summit
April 18 2017 - 8:43AM
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI) announced that
Dyadic’s Vice President of Research and Development, Dr. Ronen
Tchelet, will present ”C1-The Journey of More Productive Cell
Expression” at PEGS 2017, The Essential Protein Engineering Summit
on Thursday, May 4, 2017 from 3:35 pm to 3:50 pm EST at the Seaport
World Trade Center, Boston, MA.
Also in attendance from Dyadic will be Mark
Emalfarb, President and Chief Executive Officer and Matthew Jones,
Managing Director of Business Development and Licensing. The Dyadic
team will conduct one-on-one meetings throughout the conference
dates of May 1 through 5, 2017. Attendees can contact Dyadic
to arrange a meeting. For registration information, please
visit the conference website at http://www.pegsummit.com.
This year’s conference theme is “The future of
next generation Biologics and Biosimilars”. Dyadic’s vision is
to position the C1 technology as the expression system of choice to
improve the speed and efficiency while reducing the costs at which
biologic vaccines and drugs are bought to market. This could
improve access and lower the cost of drugs for patients and the
health care system, and most importantly, save lives.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical protein production
system based on the fungus Myceliopthora thermophila, nicknamed C1.
The C1 microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, production and performance of biologic
vaccines and drugs at flexible commercial scales. Dyadic is
using the C1 technology and other technologies to conduct research,
development and commercial activities for the development and
manufacturing of human and animal vaccines, monoclonal antibodies,
biosimilars and/or biobetters, and other therapeutic proteins.
Dyadic pursues research & development collaborations, licensing
arrangements and other commercial opportunities with its partners
and collaborators to leverage the value and benefits of these
technologies in developing and manufacturing biopharmaceuticals
which these technologies help produce. In particular, as the aging
population grows in developed and undeveloped countries, Dyadic
believes the C1 technology may help bring biologic drugs to market
faster, in greater volumes, at lower cost, and with new properties
to drug developers and manufacturers and, hopefully, improve access
and cost to patients and the healthcare system, but most
importantly saving lives.
Please visit Dyadic’s website at
www.dyadic.com for additional information, including details
regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions; (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives; (3) Dyadic’s ability to retain and attract employees,
consultants, directors and advisors; (4) our ability to implement
and successfully carry out Dyadic’s and third parties research and
development efforts; (5) our ability to obtain new license and
research agreements; (6) our ability to maintain our existing
access to, and/or expand access to third party contract research
organizations in order to carry out our research projects for
ourselves and third parties; (7) competitive pressures and reliance
on key customers and collaborators; and; (8) other factors
discussed in Dyadic’s publicly available filings, including
information set forth under the caption “Risk Factors” in our
December 31, 2016 Annual Report (with Amended Audit Report) filed
with the OTC Markets on March 24, 2017. New risks and uncertainties
arise from time to time, and it is impossible for us to predict
these events or how they may affect us.
Contact:
Dyadic International, Inc.
Mark Emalfarb
Chief Executive Officer
Phone: 561-743-8333
Email: memalfarb@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024